

BIOSPECIFICS TECHNOLOGIES CORP

Form 8-K

November 13, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 13, 2014**

BIOSPECIFICS TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-34236
(Commission
File Number)

11-3054851
(IRS Employer
Identification No.)

35 Wilbur Street
Lynbrook, NY
(Address of principal executive offices)

11563
(Zip Code)

Registrant's telephone number, including area code: **516.593.7000**

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Introductory Comment

Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpeci Technologies Corp.

Item 7.01 Regulation FD Disclosure

The presentation materials, furnished as Exhibit 99.1 hereto and which are incorporated herein by reference, will be used by officers and other representatives of the Company in meetings with potential investors and stockholders during the month of November and will be used first on November 14, 2014.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

<u>Exhibit</u> <u>No.</u>	<u>Description</u>
------------------------------	--------------------

99.1	Presentation materials to be used by officers and other representatives of the Company
------	----------------------------------------------------------------------------------------

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 13, 2014

BioSpecifics Technologies Corp.

By: /s/ Thomas L. Wegman
Name: Thomas L. Wegman
Title: President

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description</u>
-----------------------	---------------------------

<u>No.</u>	<u>Description</u>
-------------------	---------------------------

99.1	<u>Presentation materials to be used by officers and representatives of the Company</u>
------	-----------------------------------------------------------------------------------------
